Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) Financial Performance & Income Statement Overview
Review Halozyme Therapeutics, Inc. (HALO) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Halozyme Therapeutics, Inc. (HALO) Income Statement & Financial Overview
Review Halozyme Therapeutics, Inc. HALO income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $264.86M | $298.008M | $290.08M | $231.35M |
| Cost of Revenue | $48.40M | $42.05M | $49.43M | $57.37M |
| Gross Profit | $216.46M | $255.95M | $240.66M | $173.98M |
| Gross Profit Ratio | $0.82 | $0.86 | $0.83 | $0.75 |
| R&D Expenses | $14.80M | $20.44M | $18.46M | $21.04M |
| SG&A Expenses | $42.36M | $42.25M | $41.24M | $35.71M |
| Operating Expenses | $74.92M | $80.45M | $77.46M | $56.75M |
| Total Costs & Expenses | $123.33M | $122.51M | $126.89M | $114.12M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $4.53M | $4.54M | $4.52M | $4.52M |
| Depreciation & Amortization | $20.45M | $20.41M | $20.36M | $20.36M |
| EBITDA | $168.80M | $203.17M | $190.03M | $137.60M |
| EBITDA Ratio | $0.64 | $0.68 | $0.66 | $0.59 |
| Operating Income | $141.53M | $175.50M | $163.20M | $117.23M |
| Operating Income Ratio | $0.53 | $0.59 | $0.56 | $0.51 |
| Other Income/Expenses (Net) | $2.29M | $2.71M | $1.95M | $508000.00 |
| Income Before Tax | $143.83M | $178.21M | $165.15M | $117.74M |
| Income Before Tax Ratio | $0.54 | $0.60 | $0.57 | $0.51 |
| Income Tax Expense | $25.73M | $41.20M | $28.14M | $24.50M |
| Net Income | $118.09M | $137.01M | $137.01M | $93.25M |
| Net Income Ratio | $0.45 | $0.46 | $0.47 | $0.40 |
| EPS | $0.96 | $1.08 | $1.08 | $0.73 |
| Diluted EPS | $0.93 | $1.06 | $1.05 | $0.72 |
| Weighted Avg Shares Outstanding | $123.22M | $126.41M | $126.85M | $127.12M |
| Weighted Avg Shares Outstanding (Diluted) | $126.64M | $129.42M | $130.13M | $129.22M |
Financial performance has remained strong, with revenue growing from $231.35M in Q2 2024 to $264.86M in Q1 2025. Gross profit continued to perform well, with margins at 82% in the latest quarter. Operating income reached $141.53M in Q1 2025, holding a steady 53% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $168.80M. Net income dropped to $118.09M, keeping EPS at $0.96. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan